Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rapid T cell–based identification of human tumor tissue antigens by automated two-dimensional protein fractionation
Philipp Beckhove, … , Andreas Unterberg, Christel Herold-Mende
Philipp Beckhove, … , Andreas Unterberg, Christel Herold-Mende
Published May 10, 2010
Citation Information: J Clin Invest. 2010;120(6):2230-2242. https://doi.org/10.1172/JCI37646.
View: Text | PDF
Technical Advance Oncology

Rapid T cell–based identification of human tumor tissue antigens by automated two-dimensional protein fractionation

  • Text
  • PDF
Abstract

Identifying the antigens that have the potential to trigger endogenous antitumor responses in an individual cancer patient is likely to enhance the efficacy of cancer immunotherapy, but current methodologies do not efficiently identify such antigens. This study describes what we believe to be a new method of comprehensively identifying candidate tissue antigens that spontaneously cause T cell responses in disease situations. We used the newly developed automated, two-dimensional chromatography system PF2D to fractionate the proteome of human tumor tissues and tested protein fractions for recognition by preexisting tumor-specific CD4+ Th cells and CTLs. Applying this method using mice transgenic for a TCR that recognizes an OVA peptide presented by MHC class I, we demonstrated efficient separation, processing, and cross-presentation to CD8+ T cells by DCs of OVA expressed by the OVA-transfected mouse lymphoma RMA-OVA. Applying this method to human tumor tissues, we identified MUC1 and EGFR as tumor-associated antigens selectively recognized by T cells in patients with head and neck cancer. Finally, in an exemplary patient with a malignant brain tumor, we detected CD4+ and CD8+ T cell responses against two novel antigens, transthyretin and calgranulin B/S100A9, which were expressed in tumor and endothelial cells. The immunogenicity of these antigens was confirmed in 4 of 10 other brain tumor patients. This fast and inexpensive method therefore appears suitable for identifying candidate T cell antigens in various disease situations, such as autoimmune and malignant diseases, without being restricted to expression by a certain cell type or HLA allele.

Authors

Philipp Beckhove, Rolf Warta, Britt Lemke, Diana Stoycheva, Frank Momburg, Martina Schnölzer, Uwe Warnken, Hubertus Schmitz-Winnenthal, Rezvan Ahmadi, Gerhard Dyckhoff, Mariana Bucur, Simone Jünger, Thomas Schueler, Volker Lennerz, Thomas Woelfel, Andreas Unterberg, Christel Herold-Mende

×

Figure 1

Fractionation, detection, and cross-presentation of recombinant OVA and OVA from OVA-overexpressing cells.

Options: View larger image (or click on image) Download as PowerPoint
Fractionation, detection, and cross-presentation of recombinant OVA and ...
(A) 1D profile of 1 mg OVA. Red area corresponds to fraction 16. (B) 2D profile of fraction 16 of recombinant OVA. Main peak (P) was eluted in W32. AU, absorbance units. (C) Confirmation of OVA protein in W32. (D) Differential expression map of 2D separation of fraction 16 of RMA-OVA and RMA cells. Among others, a peak at RT = 24.4 minutes was detected in RMA-OVA but not RMA fraction and eluted to W33. (E) Confirmation of OVA protein in W33 of RMA-OVA cells only. (C and E) PBS served as negative and recombinant OVA as positive control (C1, 0.5 ng; C2, 5 ng). (F) DCs from C57BL/6 mice pulsed with fractionated recombinant OVA (W32, B) were used to stimulate OVA-specific T cells. T cells stained with CD8- and CD69-PE to evaluate the proportion of early-activated T cells by flow cytometry showed dose-dependent OVA-specific T cell activation. (G and H) DCs pulsed with proteins derived from OVA-positive 2D fraction of RMA-OVA or respective fraction from RMA cells (W33; E). (G) T cell activation as determined by flow cytometry with anti-CD69 antibodies. In F and G, one representative experiment of 3 independent experiments is shown. (H) Proliferative activity of purified CD8+ OVA-specific T cells after activation with DCs loaded with fractions W33 from RMA-OVA or RMA cells or after activation with unpulsed DCs as determined by thymidine incorporation. Mean + SD of 2 independent experiments is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts